Indoco Remedies Limited — Investor Meet, 04-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

The company reported Q1 consolidated revenue of INR 466.2 Cr, an 8.2% YoY increase, with standalone revenue up 5.8% to INR 408.1 Cr. Consolidated EBITDA stood at INR 41 Cr (8.8% margin). The API business saw robust growth of 42.4% to INR 52.1 Cr, and US business revenue surged 62.2% to INR 45.9 Cr. Domestic formulations remained flat, primarily due to seasonal product impacts, while international formulations grew modestly by 2.8%.

Management is prioritizing scaling domestic brands and leveraging R&D for high-value international filings. Significant cost optimization efforts, including a 26% reduction in batch manufacturing and about 1,100 fewer personnel, have boosted efficiency. Total debt has decreased to INR 930 Cr, with plans to repay INR 260 Cr over the next 7-18 months. While the critical USFDA audit for sterile plants is still awaited, Europe is expected to rebound. The company targets a 12-15% sales CAGR for the coming years with minimal capital expenditure.